Introduction to PDABs: How US states are addressing high-cost prescription drugs
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.
Chris Nüesch
Vice President
Chris Nüesch is a vice president in the Life Sciences Practice at CRA, with 15 years of experience helping clients tackle a range of challenges across market access, commercialization, and brand strategy.
Chris has deep expertise addressing client questions across the specialty disease space including rare disease, respiratory, oncology, and cell & gene therapy. Notable work includes the stand-up of a health system engagement strategy for a portfolio of specialty products, and the brand and marketing strategy for a series of indication expansions for a solid tumor oncology agent.
His project work is often data-driven, either through the analysis of patient-level claims data or through the application of robust primary market research approaches.
Prior to joining CRA, Chris held a series of progressive roles at leading life sciences strategy consulting firms. Chris holds a bachelor’s degree in Biology from the University of Pennsylvania, an MA in Biology from Columbia University, and an MBA in Finance from the NYU Stern School of Business.
Credentials
Get In Touch
Chris Nüesch